Biomarin Pharmaceutical (WBO:BMRN) 3-Year EPS without NRI Growth Rate : -21.60% (As of Dec. 2023)

View and export this data going back to 2017. Start your Free Trial

What is Biomarin Pharmaceutical 3-Year EPS without NRI Growth Rate?

Biomarin Pharmaceutical's EPS without NRI for the three months ended in Dec. 2023 was €0.45.

During the past 12 months, Biomarin Pharmaceutical's average EPS without NRI Growth Rate was 800.40% per year. During the past 3 years, the average EPS without NRI Growth Rate was -21.60% per year. Please click Growth Rate Calculation Example (GuruFocus) to see how GuruFocus calculates Wal-Mart Stores Inc (WMT)'s revenue growth rate. You can apply the same method to get the average EPS without NRI growth rate.

During the past 13 years, the highest 3-Year average EPS without NRI Growth Rate of Biomarin Pharmaceutical was 56.80% per year. The lowest was -36.50% per year. And the median was -0.70% per year.

Competitive Comparison of Biomarin Pharmaceutical's 3-Year EPS without NRI Growth Rate

For the Biotechnology subindustry, Biomarin Pharmaceutical's 3-Year EPS without NRI Growth Rate, along with its competitors' market caps and 3-Year EPS without NRI Growth Rate data, can be viewed below:

* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.

Biomarin Pharmaceutical's 3-Year EPS without NRI Growth Rate Distribution in the Biotechnology Industry

For the Biotechnology industry and Healthcare sector, Biomarin Pharmaceutical's 3-Year EPS without NRI Growth Rate distribution charts can be found below:

* The bar in red indicates where Biomarin Pharmaceutical's 3-Year EPS without NRI Growth Rate falls into.

Biomarin Pharmaceutical 3-Year EPS without NRI Growth Rate Calculation

This is the 3-year average growth rate of EPS without NRI. The growth rate is calculated using exponential compounding based on the latest four year annual data.

Please click Growth Rate Calculation Example (GuruFocus) to see how GuruFocus calculates Wal-Mart Stores Inc (WMT)'s revenue growth rate. You can apply the same method to get the average EPS without NRI growth rate.

Biomarin Pharmaceutical (WBO:BMRN) 3-Year EPS without NRI Growth Rate Explanation

EPS without NRI is the amount of earnings without non-recurring items per outstanding share of the company's stock.

Earnings Per Share (EPS) is the single most important variable used by Wall Street in determining the earnings power of a company. But investors need to be aware that Earnings per Share can be easily manipulated by adjusting depreciation and amortization rate or non-recurring items. That's why GuruFocus lists Earnings per share without Non-Recurring Items, which better reflects the company's underlying performance.

Biomarin Pharmaceutical 3-Year EPS without NRI Growth Rate Related Terms

Thank you for viewing the detailed overview of Biomarin Pharmaceutical's 3-Year EPS without NRI Growth Rate provided by GuruFocus.com. Please click on the following links to see related term pages.

Biomarin Pharmaceutical (WBO:BMRN) Business Description

Industry

GURUFOCUS.COM » STOCK LIST » Healthcare » Biotechnology » Biomarin Pharmaceutical Inc (WBO:BMRN) » Definitions » 3-Year EPS without NRI Growth Rate

Comparable Companies

Traded in Other Exchanges

BMRN:USA 1BMRN:Italy BM8:Germany B1MR34:Brazil

Address

770 Lindaro Street, San Rafael, CA, USA, 94901

Website

http://www.bmrn.com

BioMarin's focus is on rare-disease therapies. Genzyme (now part of Sanofi) markets Aldurazyme through its joint venture with BioMarin, and BioMarin markets Naglazyme, Vimizim, and Brineura independently. BioMarin also markets Kuvan and Palynziq to treat the rare metabolic disorder PKU (in addition to long-standing U.S. rights, BioMarin has reacquired international rights for Kuvan and Palynziq from Merck KGaA). Voxzogo (vosoritide) was approved in achondroplasia in 2021. BioMarin's Roctavian (hemophilia A gene therapy) was approved in Europe in 2022 and in the U.S. in 2023.